Amarin Highlights Findings from Investigator-Initiated Phase 3 EMT2 Trial

Article summary

Amarin Corporation plc announced findings from the University of Leeds-sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2), which evaluated the use of icosapent ethyl in patients undergoing liver resection for colorectal cancer liver metastases.